Harrow Health, Inc. 8.625% Senior Notes due 2026 Logo

Harrow Health, Inc. 8.625% Senior Notes due 2026

HROWL

(0.5)
Stock Price

25,57 USD

-12.41% ROA

-51.28% ROE

-54.78x PER

Market Cap.

351.571.212,00 USD

250.41% DER

8.83% Yield

-18.75% NPM

Harrow Health, Inc. 8.625% Senior Notes due 2026 Stock Analysis

Harrow Health, Inc. 8.625% Senior Notes due 2026 Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Harrow Health, Inc. 8.625% Senior Notes due 2026 Fundamental Stock Analysis
# Analysis Rating
1 Assets Growth

Over the past three years, this company's revenue has consistently grown, demonstrating a positive financial trend that makes it an appealing choice.

2 Dividend

Investors can take comfort in the fact that the company has consistently distributed dividends over the past three years, demonstrating a commitment to rewarding shareholders.

3 ROE

Negative ROE (-98.25%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

4 ROA

The stock's ROA (-14.81%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

5 PBV

The stock's elevated P/BV ratio (31.31x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

6 DER

The company has a high debt to equity ratio (792%), which means it owes a lot of money compared to what it actually owns, making it financially risky.

7 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

8 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

9 Graham Number

The company's Graham number indicates that it is overvalued compared to its stock price, suggesting a potentially unfavorable investment opportunity.

10 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (-35.617), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

Harrow Health, Inc. 8.625% Senior Notes due 2026 Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Harrow Health, Inc. 8.625% Senior Notes due 2026 Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Harrow Health, Inc. 8.625% Senior Notes due 2026 Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Harrow Health, Inc. 8.625% Senior Notes due 2026 Revenue
Year Revenue Growth
2007 0
2009 0 0%
2010 0 0%
2011 0 0%
2012 100.000 100%
2013 10.000.000 99%
2014 1.660.246 -502.32%
2015 9.716.000 82.91%
2016 19.942.000 51.28%
2017 26.774.000 25.52%
2018 41.372.000 35.28%
2019 51.165.000 19.14%
2020 48.871 -104593.99%
2021 72.476 32.57%
2022 88.595 18.19%
2023 137.060.000 99.94%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Harrow Health, Inc. 8.625% Senior Notes due 2026 Research and Development Expenses
Year Research and Development Expenses Growth
2007 1.832.744
2009 0 0%
2010 194.588 100%
2011 111.554 -74.43%
2012 1.298.503 91.41%
2013 1.616.082.000 99.92%
2014 236.660 -682770.79%
2015 332.000 28.72%
2016 739.000 55.07%
2017 413.000 -78.93%
2018 825.000 49.94%
2019 2.083.000 60.39%
2020 2.413 -86224.08%
2021 11.084 78.23%
2022 3.050 -263.41%
2023 5.684.000 99.95%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Harrow Health, Inc. 8.625% Senior Notes due 2026 General and Administrative Expenses
Year General and Administrative Expenses Growth
2007 0
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 8.087.316 100%
2015 12.504.000 35.32%
2016 17.569.000 28.83%
2017 17.960.000 2.18%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Harrow Health, Inc. 8.625% Senior Notes due 2026 EBITDA
Year EBITDA Growth
2007 -4.284.540
2009 0 0%
2010 -2.502.560 100%
2011 -939.228 -166.45%
2012 -4.178.877 77.52%
2013 -7.686.879.000 99.95%
2014 -10.146.749 -75657.06%
2015 -14.822.000 31.54%
2016 -15.882.000 6.67%
2017 -12.163.000 -30.58%
2018 -5.217.000 -133.14%
2019 -4.803.000 -8.62%
2020 701 685264.05%
2021 -23.310 103.01%
2022 -6.763 -244.67%
2023 6.976.000 100.1%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Harrow Health, Inc. 8.625% Senior Notes due 2026 Gross Profit
Year Gross Profit Growth
2007 0
2009 0 0%
2010 0 0%
2011 0 0%
2012 100.000 100%
2013 10.000.000 99%
2014 567.407 -1662.4%
2015 4.510.000 87.42%
2016 10.111.000 55.4%
2017 13.269.000 23.8%
2018 24.851.000 46.61%
2019 34.416.000 27.79%
2020 34.408 -99923.25%
2021 54.262 36.59%
2022 63.212 14.16%
2023 96.792.000 99.93%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Harrow Health, Inc. 8.625% Senior Notes due 2026 Net Profit
Year Net Profit Growth
2007 -4.284.540
2009 0 0%
2010 -2.531.228 100%
2011 -1.053.936 -140.17%
2012 -5.583.535 81.12%
2013 -7.643.124.000 99.93%
2014 -10.118.103 -75439.1%
2015 -15.899.000 36.36%
2016 -19.087.000 16.7%
2017 -11.985.000 -59.26%
2018 14.625.000 181.95%
2019 168.000 -8605.36%
2020 -3.357.000 105%
2021 -18.479.000 81.83%
2022 -14.086 -131086.99%
2023 -17.564.000 99.92%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Harrow Health, Inc. 8.625% Senior Notes due 2026 Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2007 0
2009 0 0%
2010 0 0%
2011 0 0%
2012 -1 100%
2013 -1 0%
2014 -1 100%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 -1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Harrow Health, Inc. 8.625% Senior Notes due 2026 Free Cashflow
Year Free Cashflow Growth
2007 -1.763.621
2008 0 0%
2009 0 0%
2010 -2.298.311 100%
2011 -291.160 -689.36%
2012 -1.900.840 84.68%
2013 -4.438.944.000 99.96%
2014 -7.020.078 -63132.12%
2015 -11.143.000 37%
2016 -18.102.000 38.44%
2017 -9.575.000 -89.05%
2018 -1.081.000 -785.75%
2019 -518.000 -108.69%
2020 -1.962 -26301.63%
2021 3.296.000 100.06%
2022 -892 369606.73%
2023 0 0%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Harrow Health, Inc. 8.625% Senior Notes due 2026 Operating Cashflow
Year Operating Cashflow Growth
2007 -1.763.621
2008 0 0%
2009 0 0%
2010 -2.298.311 100%
2011 -291.160 -689.36%
2012 -1.900.840 84.68%
2013 -4.438.944.000 99.96%
2014 -7.055.428 -62815.3%
2015 -11.143.000 36.68%
2016 -11.215.000 0.64%
2017 -8.803.000 -27.4%
2018 687.000 1381.37%
2019 950.000 27.68%
2020 -1.100 86463.64%
2021 5.082.000 100.02%
2022 1.705 -297964.52%
2023 0 0%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Harrow Health, Inc. 8.625% Senior Notes due 2026 Capital Expenditure
Year Capital Expenditure Growth
2007 0
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 -35.350 100%
2015 0 0%
2016 6.887.000 100%
2017 772.000 -792.1%
2018 1.768.000 56.33%
2019 1.468.000 -20.44%
2020 862 -170201.62%
2021 1.786.000 99.95%
2022 2.597 -68671.66%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Harrow Health, Inc. 8.625% Senior Notes due 2026 Equity
Year Equity Growth
2007 0
2008 4.571.842 100%
2009 577.211 -692.06%
2010 -1.038.222 155.6%
2011 -1.700.005 38.93%
2012 9.996.437 117.01%
2013 15.110.738.000 99.93%
2014 8.150.174 -185303.87%
2015 -1.385.000 688.46%
2016 6.432.000 121.53%
2017 2.615.000 -145.97%
2018 24.751.000 89.43%
2019 27.418.000 9.73%
2020 -327.817 8463.81%
2021 -344.069 4.72%
2022 -327.405 -5.09%
2023 75.402.000 100.43%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Harrow Health, Inc. 8.625% Senior Notes due 2026 Assets
Year Assets Growth
2007 0
2008 5.335.835 100%
2009 1.672.084 -219.11%
2010 352.292 -374.63%
2011 160.957 -118.87%
2012 10.705.996 98.5%
2013 15.761.365.000 99.93%
2014 10.242.224 -153786.16%
2015 14.131.000 27.52%
2016 27.247.000 48.14%
2017 23.917.000 -13.92%
2018 49.451.000 51.63%
2019 59.085.000 16.31%
2020 57.474 -102703.01%
2021 98.329 41.55%
2022 157.378 37.52%
2023 286.065.000 99.94%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Harrow Health, Inc. 8.625% Senior Notes due 2026 Liabilities
Year Liabilities Growth
2007 0
2008 763.993 100%
2009 1.094.873 30.22%
2010 1.390.514 21.26%
2011 1.860.962 25.28%
2012 709.559 -162.27%
2013 650.627.000 99.89%
2014 2.092.050 -30999.97%
2015 15.516.000 86.52%
2016 20.815.000 25.46%
2017 21.302.000 2.29%
2018 24.700.000 13.76%
2019 31.667.000 22%
2020 30.646 -103231.59%
2021 87.398 64.94%
2022 130.138 32.84%
2023 210.663.000 99.94%

Harrow Health, Inc. 8.625% Senior Notes due 2026 Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
2.74
Net Income per Share
-0.45
Price to Earning Ratio
-54.78x
Price To Sales Ratio
3.74x
POCF Ratio
-143.12
PFCF Ratio
-60.14
Price to Book Ratio
11.04
EV to Sales
5.07
EV Over EBITDA
89.67
EV to Operating CashFlow
-81.38
EV to FreeCashFlow
-81.37
Earnings Yield
-0.02
FreeCashFlow Yield
-0.02
Market Cap
0,35 Bil.
Enterprise Value
0,48 Bil.
Graham Number
4.71
Graham NetNet
-3.7

Income Statement Metrics

Net Income per Share
-0.45
Income Quality
0.88
ROE
-0.51
Return On Assets
-0.08
Return On Capital Employed
0
Net Income per EBT
1.03
EBT Per Ebit
-29.24
Ebit per Revenue
0.01
Effective Tax Rate
-0.03

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.04
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.7
Operating Profit Margin
0.01
Pretax Profit Margin
-0.18
Net Profit Margin
-0.19

Dividends

Dividend Yield
0.09
Dividend Yield %
8.83
Payout Ratio
0
Dividend Per Share
2.16

Operating Metrics

Operating Cashflow per Share
-0.17
Free CashFlow per Share
-0.17
Capex to Operating CashFlow
0
Capex to Revenue
-0
Capex to Depreciation
-0
Return on Invested Capital
-0.02
Return on Tangible Assets
-0.12
Days Sales Outstanding
71.78
Days Payables Outstanding
0
Days of Inventory on Hand
114.87
Receivables Turnover
5.08
Payables Turnover
0
Inventory Turnover
3.18
Capex per Share
-0

Balance Sheet

Cash per Share
1,92
Book Value per Share
2,21
Tangible Book Value per Share
-2.56
Shareholders Equity per Share
2.21
Interest Debt per Share
5.07
Debt to Equity
2.5
Debt to Assets
0.66
Net Debt to EBITDA
23.39
Current Ratio
5.8
Tangible Asset Value
-0,09 Bil.
Net Current Asset Value
-0,10 Bil.
Invested Capital
2.5
Working Capital
0,09 Bil.
Intangibles to Total Assets
0.57
Average Receivables
0,02 Bil.
Average Payables
0,00 Bil.
Average Inventory
8739500
Debt to Market Cap
0.54

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Harrow Health, Inc. 8.625% Senior Notes due 2026 Dividends
Year Dividends Growth
2021 1
2022 2 100%
2023 2 0%

Harrow Health, Inc. 8.625% Senior Notes due 2026 Profile

About Harrow Health, Inc. 8.625% Senior Notes due 2026

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.

CEO
Mark L. Baum
Employee
217
Address

Nashville,

Harrow Health, Inc. 8.625% Senior Notes due 2026 Executives & BODs

Harrow Health, Inc. 8.625% Senior Notes due 2026 Executives & BODs
# Name Age

Harrow Health, Inc. 8.625% Senior Notes due 2026 Competitors